Want to join the conversation?
Specialty pharma company $MNK said the US FDA has granted its request for a Fast-Track designation for its Investigational New Drug application for Synacthen Depot for treating Duchenne muscular dystrophy. Synacthen Depot is approved and marketed outside US for some autoimmune and inflammatory conditions but has not been approved in the US.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$